Bristol Myers Squibb Company (NYSE:BMY) Position Cut by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd decreased its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,728,989 shares of the biopharmaceutical company's stock after selling 213,391 shares during the period. Bristol Myers Squibb makes up approximately 0.9% of AustralianSuper Pty Ltd's investment portfolio, making the stock its 22nd biggest position. AustralianSuper Pty Ltd owned 0.13% of Bristol Myers Squibb worth $166,441,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. South Dakota Investment Council boosted its position in shares of Bristol Myers Squibb by 0.9% during the first quarter. South Dakota Investment Council now owns 431,279 shares of the biopharmaceutical company's stock valued at $26,304,000 after buying an additional 3,787 shares during the period. Kestra Private Wealth Services LLC boosted its position in shares of Bristol Myers Squibb by 1.9% during the first quarter. Kestra Private Wealth Services LLC now owns 170,104 shares of the biopharmaceutical company's stock valued at $10,375,000 after buying an additional 3,092 shares during the period. St. Louis Trust Co boosted its position in shares of Bristol Myers Squibb by 11.6% during the first quarter. St. Louis Trust Co now owns 33,158 shares of the biopharmaceutical company's stock valued at $2,022,000 after buying an additional 3,451 shares during the period. Allegiance Financial Group Advisory Services LLC boosted its position in shares of Bristol Myers Squibb by 7.6% during the first quarter. Allegiance Financial Group Advisory Services LLC now owns 5,177 shares of the biopharmaceutical company's stock valued at $316,000 after buying an additional 365 shares during the period. Finally, Nwam LLC boosted its position in shares of Bristol Myers Squibb by 10.7% during the first quarter. Nwam LLC now owns 20,458 shares of the biopharmaceutical company's stock valued at $1,248,000 after buying an additional 1,985 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the acquisition, the executive vice president owned 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on BMY shares. Argus raised Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Jefferies Financial Group dropped their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus target price of $57.69.

Bristol Myers Squibb Stock Down 1.4%

Shares of Bristol Myers Squibb stock traded down $0.66 during trading on Friday, hitting $47.40. 10,713,205 shares of the stock were exchanged, compared to its average volume of 12,764,805. The stock has a market cap of $96.46 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 2.44 and a beta of 0.36. The firm's 50-day moving average price is $47.47 and its 200 day moving average price is $52.91. Bristol Myers Squibb Company has a 12-month low of $41.90 and a 12-month high of $63.33. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business's quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($4.40) earnings per share. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.23%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.